GRI vs. LSDI, PBLA, BDRX, NBSE, INM, ATNF, NLSP, SBFM, PRFX, and EVLO
Should you be buying GRI Bio stock or one of its competitors? The main competitors of GRI Bio include Lucy Scientific Discovery (LSDI), Panbela Therapeutics (PBLA), Biodexa Pharmaceuticals (BDRX), NeuBase Therapeutics (NBSE), InMed Pharmaceuticals (INM), 180 Life Sciences (ATNF), NLS Pharmaceutics (NLSP), Sunshine Biopharma (SBFM), PainReform (PRFX), and Evelo Biosciences (EVLO). These companies are all part of the "pharmaceutical preparations" industry.
Lucy Scientific Discovery (NASDAQ:LSDI) and GRI Bio (NASDAQ:GRI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, community ranking, institutional ownership, earnings, media sentiment and analyst recommendations.
In the previous week, GRI Bio had 1 more articles in the media than Lucy Scientific Discovery. MarketBeat recorded 3 mentions for GRI Bio and 2 mentions for Lucy Scientific Discovery. Lucy Scientific Discovery's average media sentiment score of 1.32 beat GRI Bio's score of 0.44 indicating that GRI Bio is being referred to more favorably in the news media.
Lucy Scientific Discovery has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500. Comparatively, GRI Bio has a beta of -1.55, meaning that its share price is 255% less volatile than the S&P 500.
Lucy Scientific Discovery received 1 more outperform votes than GRI Bio when rated by MarketBeat users.
GRI Bio's return on equity of -294.74% beat Lucy Scientific Discovery's return on equity.
Lucy Scientific Discovery has higher revenue and earnings than GRI Bio.
72.6% of Lucy Scientific Discovery shares are owned by institutional investors. Comparatively, 34.0% of GRI Bio shares are owned by institutional investors. 16.8% of GRI Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Lucy Scientific Discovery beats GRI Bio on 8 of the 11 factors compared between the two stocks.
Get GRI Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for GRI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
